Lung Therapeutics

OverviewSuggest Edit

Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. Its two lead drug candidates are LTI-01, a pro-enzyme for the treatment of loculated pleural effusion (LPE), and LTI-03, a peptide drug targeting the survival of lung epithelial cells and the inhibition of the negative effects of fibroblast proliferation in idiopathic pulmonary fibrosis patients.

TypePrivate
Founded2013
HQAustin, TX, US
Websitelungtx.com

Latest Updates

Employees (est.) (Jul 2021)15
Cybersecurity ratingAMore

Key People/Management at Lung Therapeutics

Brian Windsor

Brian Windsor

Chief Executive Officer
Steven Idell

Steven Idell

Founder and Chief Scientific Officer, Board Member
Charles Garner

Charles Garner

Chief Financial Officer
Laura Emery

Laura Emery

Head of Clinical Operations
Cory M. Hogaboam

Cory M. Hogaboam

Chief Scientist
Matt Karpen

Matt Karpen

Director of CMC
Show more

Lung Therapeutics Office Locations

Lung Therapeutics has an office in Austin
Austin, TX, US (HQ)
2600 Vía Fortuna #360
Show all (1)

Lung Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Lung Therapeutics total Funding

$53.9 m

Lung Therapeutics latest funding size

$36 m

Time since last funding

2 years ago

Lung Therapeutics investors

Lung Therapeutics's latest funding round in June 2019 was reported to be $36 m. In total, Lung Therapeutics has raised $53.9 m
Show all financial metrics

Lung Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Lung Therapeutics Online and Social Media Presence

Embed Graph

Lung Therapeutics News and Updates

Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

Taiho Pharmaceutical Co., Ltd, (“Taiho”) and Lung Therapeutics, Inc. (“Lung Tx”) announced today an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Ja…

Lung Therapeutics Receives SBIR Award for Kidney Fibrosis Research; Principal Investigator BreAnne Mackenzie Will Speak at 4th Annual IPF Summit 2020/Digital

Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, has been awarded a Small Business Innovation Research (SBIR) Grant of $300,228 from the National Institutes of Health (NIH) to study potential therapies that target fi…

Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical Pipeline

Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, announced today the closing of $36 million Series C financing. To date, Lung Therapeutics has raised a total of $53 million in outside funding

Lung Therapeutics Blogs

Lung Therapeutics, Inc. Raises $36 Million in Series C Financing to Advance Clinical Pipeline

Proceeds to fund completion of Phase II Clinical Trial for drug candidate LTI-01 in Loculated Pleural Effusions and Phase I Clinical Trial for Idiopathic Pulmonary Fibrosis (IPF) candidate LTI-03 AUSTIN, Texas–(BUSINESS WIRE)—Lung Therapeutics, Inc., a clinical stage biopharmaceutical company develo…

Lung Therapeutics, Inc. Announces New Chief Financial Officer and Board Member

AUSTIN, TX, February 4, 2019 – Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary indications, announced today the hiring of Charles T. Garner as Chief Financial Officer and the appointment of R.A. Session, II, to the company’s Boa…

Lung Therapeutics Frequently Asked Questions

  • When was Lung Therapeutics founded?

    Lung Therapeutics was founded in 2013.

  • Who are Lung Therapeutics key executives?

    Lung Therapeutics's key executives are Brian Windsor, Steven Idell and Charles Garner.

  • How many employees does Lung Therapeutics have?

    Lung Therapeutics has 15 employees.

  • Who are Lung Therapeutics competitors?

    Competitors of Lung Therapeutics include TFF Pharmaceuticals, Praedicare Labs and ReViral.

  • Where is Lung Therapeutics headquarters?

    Lung Therapeutics headquarters is located at 2600 Vía Fortuna #360, Austin.

  • Where are Lung Therapeutics offices?

    Lung Therapeutics has an office in Austin.

  • How many offices does Lung Therapeutics have?

    Lung Therapeutics has 1 office.